Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Could a single shot of naloxone after a seizure save lives?

NCT ID NCT02332447

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a single dose of naloxone, given right after a generalized tonic-clonic seizure, can help people with epilepsy breathe better and avoid sudden death. Researchers enrolled 485 adults with drug-resistant epilepsy who were already in the hospital for monitoring. The goal was to see if naloxone could speed up recovery of oxygen levels after a seizure, compared to a placebo.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
naloxone
What this could lead to
If it works, this could point toward a way to prevent sudden death in epilepsy by using a drug that blocks opioids to restore normal breathing after a seizure.
What could go wrong
This is a proof-of-concept study testing a single dose right after a seizure, not a long-term solution. It may not work in real-world settings, and blocking opioids could theoretically worsen seizures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

485 people

The number who actually took part.

Started

Jun 2015

Finished

Jul 2020

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * For inclusion * Adult patient (≥ 18 years) suffering from drug-resistant partial epilepsy * Patient undergoing long-term video-EEG monitoring in one of the participating centre to record and characterize its seizure * Patient who gave its written informed consent to participate to the study For randomization * Patient who suffers a secondary generalized tonic-clonic seizure during the long-term video-EEG monitoring while being supervised by a nurse or a physician Exclusion Criteria: * Age \< 18 years * Patient that has already been randomized in this study * Pregnant or breastfeeding women * Hypersensitivity to naloxone * History of severe heart disease (myocardial infarction, heart failure disorder, arrhythmia severe hypertension) * Ongoing opioïd treatment, including both pure agonists and partial agonists * Addiction to opioïds, heroin, or any similar substance * Patient participating in another drug trial for less than 2 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Drug-resistant partial epilepsy are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epilepsy focal epilepsy Sudden Unexpected Death in Epilepsy visual epilepsy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Service de Neurologie Fonctionnelle et d'Epileptologie et Institut des Epilepsies Hôpital Neurologique

    Lyon, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.